(Press-News.org) In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment.
This tool is a type of molecular residual disease (MRD)detector, which is used after patients have completed their primary treatment in order to monitor their cancer status. Researchers say it could inform clinical intervention, including whether to restart or intensify treatment.
“MRD detection is the future — allowing us to monitor patients in real-time,” said the study’s first author, Dr. Roy Herbst, deputy director of Yale Cancer Center and chief of medical oncology and hematology at Yale School of Medicine. “The data is strong and we're excited that our approach can now be incorporated into future studies.”
The study findings, published in Nature Medicine on March 17, were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with non-small cell lung cancer (NSCLC) with epidermal growth factor (EGFR)-activated mutations. The ADAURA trial findings showed a significant benefit in disease-free survival with osimertinib, compared to placebo, making it the recommended standard of treatment for patients up to three years after surgery.
“We know patients benefited from osimertinib in the ADAURA trial, but we want to know if they are cured or whether their cancer will come back,” said Herbst, who is also the assistant dean for translational research at Yale School of Medicine. “MRD detection is a more personalized approach for patients with EGFR mutations in the adjuvant setting [after the primary treatment has completed], and now we're understanding at what point patients start to benefit and how we can more precisely target their therapy.”
As noted in the discussion portion of the Nature Medicine report, if MRD proves valid for clinical purposes it could improve outcomes by identifying high-risk patients who might benefit from intensifying or restarting treatment. Conversely, MRD could also identify patients with low risk of recurrence, possibly sparing them from further treatment and any associated drug toxicities as a result.
Joining Herbst was co-senior author Yi-Long Wu from the Guangdong Lung Cancer Institute. Research reported in this release and the ADAURA study was funded by AstraZeneca.
END
A post-treatment blood test could inform future cancer therapy decisions
2025-03-17
ELSE PRESS RELEASES FROM THIS DATE:
Bridging Nature and Nurture: Study reveals brain's flexible foundation from birth
2025-03-17
Riddle me this: how can it be that reading these words activates nearly identical word-sensitive patches of the brain’s visual system in you and nearly every other reader of this story? And that a different set of face-sensitive visual regions—again in almost identical positions in each reader’s brain—would activate to process the faces of the researchers, should you meet them?
For years, researchers have debated how our brains consistently develop areas specialized for recognizing faces, objects, words, and places, despite individuals having vastly different life experiences.
Two competing theories have dominated this discussion. One ...
Newborns with heart defects may face a higher risk of developing childhood cancer
2025-03-17
Research Highlights:
Newborns with congenital heart defects may have a higher risk of developing childhood cancer compared to children born without a heart abnormality.
Congenital heart defects in newborns may also signal an elevated cancer risk for their mothers.
Researchers suggest a multidisciplinary team of health care professionals to care for newborns with congenital heart defects and their moms.
Embargoed until 4 a.m. CT/5 a.m. ET Monday, March 17, 2025
DALLAS, March 17, 2025 — Being born with a heart defect may ...
Continued medication important for heart failure patients
2025-03-17
Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalisation if they stop taking heart failure medications. This is according to a new study from Karolinska Institutet published in the top-ranked journal Circulation.
“Our finding raises awareness about the importance of implementing and not withdrawing medical treatments in daily clinical practice even if patients with heart failure experience an improvement in symptoms and pump function,” says the study’s last author Gianluigi Savarese, docent and senior ...
Tools to succeed: Learning support for new nurses
2025-03-17
First-year nurses often have difficulties while bridging the gap between educational theory and required workplace practice. In the fast-paced medical field, sufficient guidance is hard to come by, so new nurses must actively learn on their feet through modeling senior nurses’ actions and techniques. There are several studies on learning from role models, but no specific tools that focus on new nurses’ learning progress through this practice.
A new tool, called the Modeling Scale for Novice Nurses, has been developed by Dr. Yayoi Nagano and Professor Yasuko Hosoda at Osaka Metropolitan University’s Graduate School of Nursing. They conducted a questionnaire on ...
A breakthrough in green hydrogen peroxide production: KIST develops carbon catalyst utilizing airborne oxygen
2025-03-17
Hydrogen peroxide is one of the world's top 100 industrial chemicals with a wide range of applications in the chemical, medical, and semiconductor industries. Currently, hydrogen peroxide is mainly produced through the anthraquinone process, but this process has several problems, including high energy consumption, the use of expensive palladium catalysts, and environmental pollution due to by-products. In recent years, an environmentally friendly method of producing hydrogen peroxide by electrochemical reduction of oxygen using inexpensive carbon catalysts has gained attention. However, this method has been limited by the high cost of injecting high-purity oxygen gas and ...
Travellers: beware of Oropouche virus. Is it the next Zika?
2025-03-17
Heading south for the winter? Oropouche virus, a new infectious disease, has been reported in travellers from Canada and the United States who visited Bolivia, Brazil, Peru, and Cuba. An article published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241440 provides an overview of this emerging virus.
Similar to viruses like dengue and Zika, Oropouche virus symptoms include fever, chills, headache, and muscle aches. The incubation period is 3–10 days, and symptoms last 2–7 days and may recur weeks later in some ...
No increased death rates, admission differences for people experiencing homelessness with severe COVID-19
2025-03-17
Did people experiencing homelessness (PEH) have worse in-hospital outcomes from COVID-19 than housed people? New research published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241282 found no differences in in-hospital deaths or hospital admission rates for PEH who visited hospital for acute COVID-19 symptoms.
“In our study, we sought to answer the question of whether experiencing homelessness is a risk factor for worse prognosis from COVID-19 illness independent of important clinical variables including age, comorbidities, vaccination status, and substance use — i.e., whether clinicians should have ...
Optimizing public placement of naloxone kits to save lives
2025-03-17
Making it easy to access naloxone kits to reverse the effects of opioid poisoning will help save lives, according to research published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241228 that looks at the best placements for these kits.
Researchers wanted to understand the best placement for public-access naloxone kits in Vancouver, British Columbia, to help prevent deaths from opioid poisoning. They compared public access strategies for more than 14 000 opioid poisonings over 6 years. They looked at placement at existing locations of take-home naloxone, at public locations like chain businesses, and at public transit ...
Burden of cardiovascular disease caused by extreme heat in Australia to more than double by 2050
2025-03-17
Hot weather is responsible for an average of almost 50,000 years of healthy life lost to cardiovascular disease every year among people in Australia, according to research published in the European Heart Journal [1] today (Monday). This equates to around 7.3% of the total burden due to illness and death from cardiovascular disease.
The study also suggests that this figure could double, or even triple, by the middle of the century, if we continue with the current trend of greenhouse gas ...
Who does Darth Vader vote for? Not the same party as Harry Potter
2025-03-17
UNDER EMBARGO UNTIL 00:01AM UK TIME ON MONDAY 17 MARCH 2025
People think that Harry Potter, Spiderman and Gandalf would vote the same way they do, whereas Darth Vader, Cruella de Vill and Joffrey Baratheon would vote for the rival party.
New research from the University of Southampton, published today [17 March] in the journal Political Science Research & Method, shows how people in the UK and USA believe that fictional characters they admire would share their voting preferences, while those they dislike would vote the other way.
The researchers also found that around one in six people recalled ...